Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling
Frontiers of Medicine · 2024-02 · 18 (1) · 128-146
DOI: 10.1007/s11684-023-1010-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers of Medicine, online erschienen am 23.10.2023. Verfasst von Yuanyuan Hao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China. Hauptthemen laut MEDLINE: Exosomes, Lymphoma, B-Cell, Lymphoma. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Tumor-derived exosomes (TEXs) enriched in immune suppressive molecules predominantly drive T-cell dysfunction and impair antitumor immunity. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for refractory and relapsed hematological malignancies, but whether lymphoma TEXs have the same impact on CAR T-cell remains unclear. Here, we demonstrated that B-cell lymphoma-derived exosomes induce the initial activation of CD19-CAR T-cells upon stimulation with exosomal CD19. However, lymphoma TEXs might subsequently induce CAR T-cell apoptosis and impair the tumor cytotoxicity of the cells because of the upregulated expression of the inhibitory receptors PD-1, TIM3, and LAG3 upon prolonged exposure. Similar results were observed in the CAR T-cells exposed to plasma exosomes from patients with lymphoma. More importantly, single-cell RNA sequencing revealed that CAR T-cells typically showed differentiated phenotypes and regulatory T-cell (Treg) phenotype conversion. By blocking transforming growth factor β (TGF-β)-Smad3 signaling with TGF-β inhibitor LY2109761, the negative effects of TEXs on Treg conversion, terminal differentiation, and immune checkpoint expression were rescued. Collectively, although TEXs lead to the initial activation of CAR T-cells, the effect of TEXs suppressed CAR T-cells, which can be rescued by LY2109761. A treatment regimen combining CAR T-cell therapy and TGF-β inhibitors might be a novel therapeutic strategy for refractory and relapsed B-cell lymphoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China.
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, 450003, China.
- Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, 325000, China.
- Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China.
- Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310009, China. leiwen2017@zju.edu.cn.
- Department of Hematology, Tongji Hospital of Tongji University, Shanghai, 200065, China. lab7182@tongji.edu.cn.
Zitieren
APA
Hao, Y., Chen, P., Guo, S., Li, M., Jin, X., Zhang, M., Deng, W., Li, P., Lei, W., Liang, A., & Qian, W. (2024). Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. Frontiers of Medicine, 18(1), 128-146. https://doi.org/10.1007/s11684-023-1010-1
Vancouver
Hao Y, Chen P, Guo S, Li M, Jin X, Zhang M, et al. Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. Frontiers of Medicine. 2024;18(1):128-146. doi:10.1007/s11684-023-1010-1
BibTeX
@article{Hao2024,
author = {Hao, Yuanyuan and Chen, Panpan and Guo, Shanshan and Li, Mengyuan and Jin, Xueli and Zhang, Minghuan and Deng, Wenhai and Li, Ping and Lei, Wen and Liang, Aibin and Qian, Wenbin},
title = {Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling},
journal = {Frontiers of Medicine},
year = {2024},
volume = {18},
number = {1},
pages = {128--146},
doi = {10.1007/s11684-023-1010-1}
}
EUVIMED